 vaccin prevent capd staphylococc infect result prospect multicentr clinic trial stabl capd patient australian new zealand center blind fashion group effect vaccin commerci prepar combin staphylococcu toxoid whole staphylococci SB normal salin solut SS incid periton exit site infect nasal carriag prospect period addit level igg iga igm trial period serum dialys serum level anti-alpha hemolysin dialys level fibronectin specif antistaphylococc antibodi period treatment SB SS incid periton catheter-rel infect nasal carriag vaccin SB signific increas level serum anti-alpha hemolysin month durat studi level increas unrel subsequ rate periton vaccin SB SS signific increas dialys level specif antibodi aureu serum level igg iga igm complement normal rang capd patient vaccin SB addit dialys level igg iga igm complement time serum level vaccin summari immunis anti-staphylococc agent success periton exit site infect capd patient